Fresh analysis suggests that individuals who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who stop traditional lifestyle programs.
Findings released in a leading medical journal shows that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Users buying such drugs need to be cognizant of the risk of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a return to original weight within about 18 months.
Analyzing Treatments
The research, which looked at 37 of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with other pills.
The team note that people who shed pounds through diet and exercise generally experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Experts believe the mechanism of the drugs explains the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the body to produce less of its endogenous GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in appetite is no longer kept in check, making overeating far more likely."
A Lifelong Disease?
Medical guidelines recommend the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals argue that, considering the high risk of relapse, the treatment is often long-term.
This opinion is echoed by pharmaceutical companies, who state that the results "underscore the long-term character of obesity," comparing it to managing diseases like diabetes.
Patient Accounts
People who have discontinued the jabs report a powerful return of cravings.
"It felt as if something that goes on and you're instantly starving," said a patient.
This difficulty is compounded if users have not adopted permanent dietary or behavioural changes during treatment.
Growing Interest
Survey data show that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is higher among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers stress that while these medications are potent tools for weight loss, they are not a standalone solution and long-term success hinges on integrated lifestyle management.